ETF overview
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.
Fund facts
- Expense ratio
- 0.75%
- Fund assets
- 2.22B USD (all share classes)
- Issuer
- ARK
- Inception date
- Oct 31, 2014
- Number of holdings
- 35
Breakdown
Holdings (35)
| Name | Ticker | Weight |
|---|---|---|
| 10X GENOMICS INC-CLASS A | TXG | 8.74% |
| TEMPUS AI INC-CL A | TEM | 8.62% |
| TWIST BIOSCIENCE CORP | TWST | 8.22% |
| CRISPR THERAPEUTICS AG | CRSP | 5.59% |
| NATERA INC | NTRA | 4.93% |
| GUARDANT HEALTH INC | GH | 4.93% |
| ILLUMINA INC | ILMN | 4.89% |
| ABSCI CORP | ABSI | 4.64% |
| ELI LILLY & CO | LLY | 4.01% |
| CAREDX INC | CDNA | 3.86% |
| and 22 more | ||
Similar ETFs
- Ark Genomic Revolution Ucits ETF AccumUSDARKG.L · Overlap 94% · Expense ratio 0.75%
- Global X - Genomics & Biotechnology ETFGNOM · Overlap 42% · Expense ratio 0.50%
- Global X - Genomics & Biotechnology UCITS ETFGNOG.L · Overlap 42% · Expense ratio 0.50%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.75%
- Fund assets
- 2.22B USD (all share classes)
- Issuer
- ARK
- Inception date
- Oct 31, 2014
- Number of holdings
- 35
| Name | Ticker | Weight |
|---|---|---|
| 10X GENOMICS INC-CLASS A | TXG | 8.74% |
| TEMPUS AI INC-CL A | TEM | 8.62% |
| TWIST BIOSCIENCE CORP | TWST | 8.22% |
| CRISPR THERAPEUTICS AG | CRSP | 5.59% |
| NATERA INC | NTRA | 4.93% |
| GUARDANT HEALTH INC | GH | 4.93% |
| ILLUMINA INC | ILMN | 4.89% |
| ABSCI CORP | ABSI | 4.64% |
| ELI LILLY & CO | LLY | 4.01% |
| CAREDX INC | CDNA | 3.86% |
| and 22 more | ||
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.
- Ark Genomic Revolution Ucits ETF AccumUSDARKG.L · Overlap 94% · Expense ratio 0.75%
- Global X - Genomics & Biotechnology ETFGNOM · Overlap 42% · Expense ratio 0.50%
- Global X - Genomics & Biotechnology UCITS ETFGNOG.L · Overlap 42% · Expense ratio 0.50%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free